wrn

WRN Inhibitor 4 (Example 107), a cyclic vinyl sulfone-based compound, serves as an inhibitor of the Werner Syndrome ATP-dependent helicase enzyme (WRN). This inhibitor is applicable in cancer research [1].

WRN Inhibitor 2 (example 118), a potent inhibitor of the WRN (Werner Syndrome ATP-dependent helicase enzyme), exhibits a pIC50 value of 7.0 or greater [1].

WRN Inhibitor 3 (example 110), a cyclic vinyl sulfone-based compound, serves as an inhibitor of the Werner Syndrome ATP-dependent helicase enzyme (WRN). It is utilized in cancer research [1].

WRN Inhibitor 5 (Example 157), a cyclic vinyl sulfone-based compound, serves as an inhibitor of Werner Syndrome ATP-dependent helicase enzyme (WRN). It is utilized in cancer research [1].

WRN Inhibitor 1 (example 7) is an inhibitor of the Werner Syndrome ATP-dependent helicase enzyme (WRN), selectively targeting its helicase domain. This compound is potentially useful for cancer research [1].

MIRA-1 (WRN Helicase Inhibitor) is a restorer of wild-type p53 conformation/cellular function and selectively inhibits Werner syndrome WRN helicase activity with an IC50 of 20 µM.

WRNA10 is a potent binding agent for HIV-1TAR RNA (IC50: 10 μM, CC50: 40 μM).

ML216 (CID-49852229) is a small molecule inhibitor of BLM helicase with an IC50 of 1.8 μM, demonstrating 28-fold selectivity against the related helicases RECQ1, RECQ5, and E. coli UvrD (IC50s > 50 μM).

NSC 617145 (NSC617145) is an inhibitor of WRN helicase that inhibits the ATPase, but not exonuclease, activity of WRN helicase in a concentration-dependent manner.

NCGC00029283 is a potent inhibitor of Werner syndrome helicase-nuclease (WRN), displaying inhibitory activity against WRN helicase with an IC 50 value of 2.3 μM. Additionally, it exhibits inhibitory effects on Bloom syndrome protein helicase (BLM) and Fanconi anemia group J protein helicase (FANCJ) with IC 50 values of 12.5 μM and 3.4 μM, respectively.

NCGC00063279 is a novel inhibitor of the werner syndrome helicase-nuclease (wrn) helicase

VVD-214 (RO7589831) is a WRN deconjugating enzyme lethal variant inhibitor with potential antitumor activity, inhibits ATP hydrolysis and deconjugating enzyme activity, and can be used in the study of proliferative diseases.

Werner syndrome RecQ helicase-IN-2 (example 57) is a potent inhibitor of the Werner syndrome RecQ DNA helicase enzyme (WRN) with potential for use in cancer research.

Werner syndrome RecQ helicase-IN-3, a potent and orally active inhibitor of Werner syndrome RecQ helicase (WRN), exhibits anticancer and antiproliferative activities with an IC50 value of 0.06 µM.

Werner syndrome RecQ helicase-IN-4 is a potent, orally active inhibitor of Werner syndrome RecQ helicase (WRN) with an IC50 of 0.06 µM, exhibiting antiproliferative and anticancer activities.

Werner syndrome RecQ helicase-IN-1 is a potent Werne r syndrome RecQ DNA deconjugase (WRN) inhibitor that can be used to study cancers such as colon and stomach cancer.

H3B-968 is a potent inhibitor of Werner syndrome protein (WRN) with an IC50 of approximately 10 nM, targeting its helicase, ATPase, and exonuclease activities. While WRN is known for its synthetic lethal activity in cancer studies, H3B-968 specifically inhibits WRN's helicase function through competitive ATP antagonism [1].